Arvinas (NASDAQ:ARVN) Stock Rating Upgraded by Wall Street Zen

Arvinas (NASDAQ:ARVN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

A number of other research analysts have also commented on ARVN. Stephens upped their price objective on shares of Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Barclays upped their price target on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. BTIG Research lifted their price objective on Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wedbush reaffirmed a “neutral” rating and issued a $9.00 target price on shares of Arvinas in a research report on Thursday, November 6th. Finally, Wells Fargo & Company lowered their price target on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Ten analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $13.12.

Arvinas Trading Down 3.6%

Shares of ARVN stock opened at $11.99 on Friday. The firm has a market capitalization of $770.00 million, a P/E ratio of -14.80 and a beta of 1.88. Arvinas has a 1 year low of $5.90 and a 1 year high of $19.05. The firm’s fifty day simple moving average is $12.36 and its 200 day simple moving average is $10.40.

Insider Activity

In other news, insider Noah Berkowitz sold 5,685 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $67,594.65. Following the sale, the insider owned 163,938 shares of the company’s stock, valued at approximately $1,949,222.82. This represents a 3.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew Saik sold 5,134 shares of the business’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $61,043.26. Following the completion of the transaction, the chief financial officer owned 159,267 shares in the company, valued at approximately $1,893,684.63. This trade represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 16,238 shares of company stock worth $193,070. Corporate insiders own 4.73% of the company’s stock.

Institutional Investors Weigh In On Arvinas

Large investors have recently bought and sold shares of the business. Armistice Capital LLC increased its holdings in Arvinas by 50.0% during the 4th quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after purchasing an additional 600,000 shares in the last quarter. TCG Crossover Management LLC bought a new position in shares of Arvinas in the third quarter valued at about $13,780,000. Geode Capital Management LLC raised its holdings in shares of Arvinas by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,585,092 shares of the company’s stock valued at $11,668,000 after buying an additional 48,296 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Arvinas by 154.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after buying an additional 903,337 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Arvinas by 791.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock worth $10,498,000 after acquiring an additional 1,267,593 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.